RUIZ-ARTACHO has nothing to disclose.Ĭonflict of interest: Dra Elias-Hernandez has nothing to disclose.Ĭonflict of interest: Dr. Lopez-Reyes has nothing to disclose.Ĭonflict of interest: Dr. Jara-Palomares reports personal fees from Actelion, personal fees from Rovi, personal fees from PFIZER, personal fees from Leo-Pharma, personal fees from GSK, outside the submitted work.Ĭonflict of interest: Dr. LEON ROMAN has nothing to disclose.Ĭonflict of interest: Dr. Rodriguez-Calle has nothing to disclose.Ĭonflict of interest: Dr. Jiménez reports personal fees from Bayer HealthCare Pharmaceuticals, personal fees from Boehringer Ingelheim, personal fees from Bristol-Myers Squibb, grants and personal fees from Daiichi Sankyo, personal fees from Leo Pharma, personal fees from Pfizer, grants and personal fees from Rovi, grants and personal fees from Sanofi, outside the submitted work.Ĭonflict of interest: Dr. Please open or download the PDF to view this article.Ĭonflict of interest: Dr. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. It is published here in its accepted form prior to copyediting and typesetting by our production team. This manuscript has recently been accepted for publication in the European Respiratory Journal. Conclusions The use of a prognostic assessment and management pathway was effective in reducing the LOS for acute PE.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |